While the Pfizer vaccine became the first to be used in a public vaccination programme on Tuesday, the Oxford/AstraZeneca vaccine team became the first to publish their results in a peer-reviewed journal, the Lancet.
As the press release announcing the results explained, the overall efficacy rate of the Oxford vaccine was measured at 70 per cent, but that concealed a large difference between different arms of the trial.
Already a subscriber? Log in
Easter flash sale:
10 issues for $1
Subscribe this Easter and get the next 10 issues of the magazine, plus website and app access, all for just $1.
- Weekly delivery of the magazine
- Unlimited access to spectator.com.au and app
- Spectator Australia podcasts and newsletters
- Full access to spectator.co.uk
Or
Comments
Easter flash sale: 10 issues for $1
Join the conversation with other Spectator Australia readers. Subscribe to leave a comment.
CLAIM OFFER 10 issues for $1Already a subscriber? Log in